Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $14,988,720.00 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. The trade was a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Pushkal Garg also recently made the following trade(s):

• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded down $4.99 during trading on Wednesday, reaching $274.20. The company's stock had a trading volume of 250,528 shares, compared to its average volume of 686,961. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a 50-day moving average price of $248.91 and a two-hundred day moving average price of $260.56. The stock has a market capitalization of $35.37 billion, a P/E ratio of -104.66 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. The business's revenue was down 33.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.15 EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp grew its stake in shares of Alnylam Pharmaceuticals by 94.9% during the second quarter. Mackenzie Financial Corp now owns 36,091 shares of the biopharmaceutical company's stock worth $8,770,000 after purchasing an additional 17,576 shares during the period. Algert Global LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $476,000. Creative Planning boosted its holdings in Alnylam Pharmaceuticals by 63.2% during the second quarter. Creative Planning now owns 8,034 shares of the biopharmaceutical company's stock worth $1,952,000 after purchasing an additional 3,110 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Alnylam Pharmaceuticals by 72.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 596 shares of the biopharmaceutical company's stock valued at $145,000 after acquiring an additional 250 shares in the last quarter. Finally, Regal Investment Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 4.1% during the 2nd quarter. Regal Investment Advisors LLC now owns 3,348 shares of the biopharmaceutical company's stock worth $814,000 after purchasing an additional 132 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. Royal Bank of Canada restated an "outperform" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, January 21st. Wolfe Research cut Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. Finally, Chardan Capital reissued a "buy" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.